File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients

TitleCeftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients
Authors
Issue Date1990
Citation
Antimicrobial Agents And Chemotherapy, 1990, v. 34 n. 7, p. 1336-1341 How to Cite?
AbstractOne hundred febrile episodes in 89 neutropenic patients after cytotoxic chemotherapy were randomized to be treated with either ceftazidime or imipenem as initial monotherapy. The clinical characteristics of the two groups of patients were comparable. The response of the fever in patients who received imipenem was significantly better than that in those who received ceftazidime (77 versus 56%, respectively; P = 0.04), especially in those with microbiologically documented infection (81 versus 33%, respectively; P = 0.02). The in vitro susceptibilities and the clinical responses suggested that, with the possible exception of Pseudomonas spp., imipenem was more effective than ceftazidime in treating neutropenic infections caused by both gram-positive and -negative organisms. An additional 23 and 21% of the patients in the ceftazidime and imipenem groups, respectively, responded to the addition of cloxacillin and amikacin following failure of monotherapy. The majority of the treatment failures, relapses, and superinfections were related to resistant infective organisms such as methicillin-resistant Staphylococcus spp. and Pseudomonas spp. or disseminated fungal infections.
Persistent Identifierhttp://hdl.handle.net/10722/161846
ISSN
2015 Impact Factor: 4.415
2015 SCImago Journal Rankings: 2.322
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorYung, Ren_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorChau, PYen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorLam, WKen_US
dc.contributor.authorTodd, Den_US
dc.date.accessioned2012-09-05T05:15:28Z-
dc.date.available2012-09-05T05:15:28Z-
dc.date.issued1990en_US
dc.identifier.citationAntimicrobial Agents And Chemotherapy, 1990, v. 34 n. 7, p. 1336-1341en_US
dc.identifier.issn0066-4804en_US
dc.identifier.urihttp://hdl.handle.net/10722/161846-
dc.description.abstractOne hundred febrile episodes in 89 neutropenic patients after cytotoxic chemotherapy were randomized to be treated with either ceftazidime or imipenem as initial monotherapy. The clinical characteristics of the two groups of patients were comparable. The response of the fever in patients who received imipenem was significantly better than that in those who received ceftazidime (77 versus 56%, respectively; P = 0.04), especially in those with microbiologically documented infection (81 versus 33%, respectively; P = 0.02). The in vitro susceptibilities and the clinical responses suggested that, with the possible exception of Pseudomonas spp., imipenem was more effective than ceftazidime in treating neutropenic infections caused by both gram-positive and -negative organisms. An additional 23 and 21% of the patients in the ceftazidime and imipenem groups, respectively, responded to the addition of cloxacillin and amikacin following failure of monotherapy. The majority of the treatment failures, relapses, and superinfections were related to resistant infective organisms such as methicillin-resistant Staphylococcus spp. and Pseudomonas spp. or disseminated fungal infections.en_US
dc.languageengen_US
dc.relation.ispartofAntimicrobial Agents and Chemotherapyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAgranulocytosis - Complicationsen_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshAntineoplastic Agents - Adverse Effectsen_US
dc.subject.meshBacteria - Drug Effectsen_US
dc.subject.meshBacterial Infections - Complications - Drug Therapy - Microbiologyen_US
dc.subject.meshCeftazidime - Therapeutic Useen_US
dc.subject.meshCilastatin - Therapeutic Useen_US
dc.subject.meshDrug Combinations - Therapeutic Useen_US
dc.subject.meshDrug Therapy, Combination - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFever - Complicationsen_US
dc.subject.meshHumansen_US
dc.subject.meshImipenem - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeutropenia - Chemically Induced - Complicationsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.titleCeftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patientsen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1128/AAC.34.7.1336-
dc.identifier.pmid2201252-
dc.identifier.pmcidPMC175977-
dc.identifier.scopuseid_2-s2.0-0025366999en_US
dc.identifier.volume34en_US
dc.identifier.issue7en_US
dc.identifier.spage1336en_US
dc.identifier.epage1341en_US
dc.identifier.isiWOS:A1990DM33500008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridYung, R=7005594277en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridChau, PY=36509704300en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats